AstraZeneca(AZN)

Search documents
AstraZeneca(AZN) - 2022 Q4 - Earnings Call Presentation
2023-02-10 14:56
Full Year and Q4 2022 Results Conference call and webcast for investors and analysts Forward-looking statements Astra ...
AstraZeneca(AZN) - 2022 Q4 - Earnings Call Transcript
2023-02-09 20:03
AstraZeneca PLC (NASDAQ:AZN) Q4 2022 Earnings Conference Call February 9, 2023 6:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director & Chief Executive Officer Aradhana Sarin - Executive Director & Chief Financial Officer David Fredrickson - Executive Vice President of Oncology Business Unit Susan Galbraith - Executive Vice President of Oncology Research & Development Ruud Dobber - Executive Vice President of BioPharmaceuticals Business Unit Menelas Pang ...
AstraZeneca (AZN) Presents At 41st Annual Healthcare Conference - Slideshow
2023-01-19 16:01
J.P. Morgan 41st Annual Healthcare Conference Aradhana Sarin Executive Director and Chief Financial Officer ...
AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript)
2020-12-15 14:50
Key Points Industry/Company Involved - **AstraZeneca PLC (NASDAQ:AZN)**: A global biopharmaceutical company focused on oncology, cardiovascular, renal metabolism, respiratory disease, and immunology. - **Alexion**: A global leader in immune-mediated rare diseases, known for its product Soliris and Ultomiris. Core Points and Arguments - **Strategic Merger**: AstraZeneca's acquisition of Alexion aims to accelerate its strategic and financial development, expand its immunology presence, and leverage Alexion's expertise in rare diseases. - **Scientific Synergy**: The merger combines AstraZeneca's precision medicine capabilities with Alexion's expertise in the complement system, creating opportunities for innovative drug development. - **Financial Benefits**: The transaction is expected to enhance profitability, cash flow, and debt deleveraging, with a goal of increasing the dividend and maintaining a strong investment-grade credit rating. - **Revenue Growth**: The combined company is projected to achieve double-digit revenue growth through 2025, driven by strong pipeline development and sales synergies in emerging markets, particularly China. Other Important Points - **Pipeline**: AstraZeneca has a robust pipeline with 17 Phase III medicines and life cycle projects, focusing on oncology, immunology, and other therapeutic areas. - **Alexion Pipeline**: Alexion's pipeline includes 11 molecules and 20 clinical studies across various indications, including rare diseases and neurology. - **Geographic Complementarity**: AstraZeneca has a strong presence in emerging markets, particularly China, which will support the expansion of Alexion's products in these regions. - **Cultural Alignment**: Both companies share a common culture of belief in science, innovation, and patient-centricity, which is expected to facilitate a smooth integration. - **Integration**: The integration is expected to be relatively straightforward, with limited disruption to existing teams and operations. References - [1]: AstraZeneca to acquire Alexion Conference Call December 12, 2020 9:00 AM ET - [2]: Company Participants - [3]: Conference Call Participants - [4]: Pascal Soriot - [5]: Pascal Soriot - [6]: Pascal Soriot - [7]: Pascal Soriot - [8]: Pascal Soriot - [9]: Pascal Soriot - [10]: Pascal Soriot - [11]: Pascal Soriot - [12]: Pascal Soriot - [13]: Pascal Soriot - [14]: Pascal Soriot - [15]: Pascal Soriot - [16]: Marc Dunoyer - [17]: Marc Dunoyer - [18]: Marc Dunoyer - [19]: Marc Dunoyer - [20]: Marc Dunoyer - [21]: Marc Dunoyer - [22]: Marc Dunoyer - [23]: Marc Dunoyer - [24]: Marc Dunoyer - [25]: Marc Dunoyer - [26]: Marc Dunoyer - [27]: Marc Dunoyer - [28]: Marc Dunoyer - [29]: Marc Dunoyer - [30]: Marc Dunoyer - [31]: Marc Dunoyer - [32]: Marc Dunoyer - [33]: Marc Dunoyer - [34]: Marc Dunoyer - [35]: Pascal Soriot - [36]: Pascal Soriot - [37]: Pascal Soriot - [38]: Question-and-Answer Session - [39]: Pascal Soriot - [40]: Marc Dunoyer - [41]: Pascal Soriot - [42]: Marc Dunoyer - [43]: Marc Dunoyer - [44]: Pascal Soriot - [45]: Marc Dunoyer - [46]: Marc Dunoyer - [47]: Pascal Soriot - [48]: James Gordon - [49]: Pascal Soriot - [50]: Marc Dunoyer - [51]: Pascal Soriot - [52]: Marc Dunoyer - [53]: Pascal Soriot - [54]: Andrew Baum - [55]: Pascal Soriot - [56]: Ludwig Hantson - [57]: Pascal Soriot - [58]: Ludwig Hantson - [59]: Ludwig Hantson - [60]: Ludwig Hantson - [61]: Ludwig Hantson - [62]: Pascal Soriot - [63]: Ludwig Hantson - [64]: Ludwig Hantson - [65]: Pascal Soriot - [66]: Marc Dunoyer - [67]: Pascal Soriot - [68]: Emmanuel Papadakis - [69]: Marc Dunoyer - [70]: Pascal Soriot - [71]: Marc Dunoyer - [72]: Pascal Soriot - [73]: Marc Dunoyer - [74]: Pascal Soriot - [75]: Marc Dunoyer - [76]: Pascal Soriot - [77]: Marc Dunoyer - [78]: Marc Dunoyer - [79]: Pascal Soriot - [80]: Marc Dunoyer - [81]: Pascal Soriot - [82]: Tim Anderson - [83]: Marc Dunoyer - [84]: Marc Dunoyer - [85]: Pascal Soriot - [86]: Marc Dunoyer - [87]: Pascal Soriot - [88]: Marc Dunoyer - [89]: Mene Pangalos - [90]: Pascal Soriot - [91]: Mene Pangalos - [92]: Marc Dunoyer - [93]: Pascal Soriot - [94]: Marc Dunoyer - [95]: Pascal Soriot - [96]: Marc Dunoyer - [97]: Pascal Soriot - [98]: Pascal Soriot - [99]: Mene Pangalos - [100]: Marc Dunoyer - [101]: Pascal Soriot - [102]: Ludwig Hantson - [103]: Pascal Soriot - [104]: Marc Dunoyer - [105]: Ludwig Hantson - [106]: Aradhana Sarin - [107]: Pascal Soriot - [108]: Marc Dunoyer - [109]: Pascal Soriot - [110]: Pascal Soriot - [111]: Ludwig Hantson - [112]: Pascal Soriot - [113]: Ludwig Hantson - [114]: Ludwig Hantson - [115]: Pascal Soriot